COGT - Company ID 0001622229
The table below shows Cogent Biosciences, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $75.36M | $68.99M | $62.20M | $63.03M | $63.61M | $54.29M |
| SG&A |
Cogent Biosciences, Inc. reported annual revenue of $7.87M for fiscal year 2020. That is down 65.0% from $22.50M in fiscal 2019. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $28.24M |
| $14.37M |
| $13.38M |
| $11.90M |
| $11.80M |
| $10.09M |
| Operating income | -$103.61M | -$83.36M | -$75.58M | -$74.93M | -$75.41M | -$64.39M |
| Income tax | - | - | - | - | - | - |
| Net income | -$97.35M | -$80.93M | -$73.53M | -$71.99M | -$70.63M | -$58.95M |
| EPS (diluted) | -$0.53 | -$0.50 | -$0.53 | -$0.52 | -$0.52 | -$0.43 |